Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive Clinical Trial

Official title:

Comparison of 18 mcg of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (2 Puffs of 20 mcg) in a Double Blind, Double Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02172443
• Other study ID #: 205.232
• Status: Completed
• Phase: Phase 3
• Start date: June 2001

Study information

• Verified date: August 2018
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to compare the bronchodilator efficacy and safety of tiotropium inhalation capsule (18 mcg once daily) and Atrovent MDI (2 puffs of 20 mcg q.i.d.) in patients with chronic obstructive pulmonary disease (COPD)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. primary completion date: May 2002
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• COPD patients with an forced expiratory volume in one second (FEV1) <= 65% of predicted normal and FEV1 <= 70% of forced vital capacity (FVC)

• Male or female patients 40 years of age or older.

• Patient must have a smoking history of more than 10 pack-years. A pack-year is defined as the equivalent of smoking on pack of cigarettes per day for a year.

• Patient must be able to perform pulmonary function test as required in the protocol.

• Patient must be able to inhale medication from the handihaler device and should have a good technique of inhaling aerosol administered from MDI.

• All patients must sign an informed consent from prior to participation in the trail, prior to pre-study washout of their usual pulmonary medication.

Exclusion Criteria:

• Patient with significant disease other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the result of the study or the patient's ability to participate in the study.

• Patients with clinically significant abnormal baseline hematology, blood chemistry or urinalysis, if the abnormality defines a disease listed as an exclusion criterion will be excluded.

• All patients with a serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) twice the upper normal limit, bilirubin 150% or creatinine 125% of the upper normal limit will be excluded regardless of the clinical condition. Repeat laboratory evaluation will be not be conducted in these subjects.

• Patients with a recent history ( i.e. one year or less) of myocardial infarction.

• Patients with a recent history ( i.e. one year or less) of heart failure or patients with any cardiac arrhythmia requiring drug therapy.

• Patients with regular use of daytime oxygen therapy.

• Patients with known active tuberculosis.

• Patients with a history of cancer within the last five years. Patients with treated basal cell carcinoma are allowed.

• Patients with a history of life-threatening pulmonary, or history of cystic fibrosis or bronchiectasis.

• Patients who have undergone pulmonary resection or a thoracotomy for any reason.

• Patients with an upper respiratory tract infection in the past 2 weeks prior to the screening visit (= Visit 1) or during the baseline period of 2-weeks (run-in period).

• Patients with known hypersensitivity to anticholinergic drugs, lactose or any other component of the inhalation capsule delivery system.

• Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction.

• Patients with known narrow-angle glaucoma.

• Patients who are being treated with cromolyn sodium or nedocromil sodium.

• Patients who are being treated with antihistamines.

• Patients using oral corticosteroid medication at unstable dosage (i.e. less than 6 weeks on a stable dose) or at a dose excess of the equivalent 10 mg of prednisone per day or 20 mg every day.

• Pregnant or nursing women or women of childbearing potential not using medically approved means of contraception (e.g. oral contraceptives, intrauterine devices, or diaphragm).

• Patients with a history of asthma, allergic rhinitis or atopy or who have a blood total eosinophil count >= 400 per microliter (males) or >= 320 per microliter (females). A repeat eosinophil count will not be conducted in these patients.

• Patients with a history and/or active alcohol or drug abuse.

• Patients who have taken an investigational drug on month or six half-lives (whichever is greater) prior to the screening visit (= Visit 1).

Related Conditions & MeSH terms

• Chronic Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• tiotropium inhalation powder capsules

• Atrovent

• placebo to Atrovent

• placebo to tiotropium inhalation capsules

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in trough forced expiratory volume in one second (FEV1)		baseline, day 29
Secondary	Change from baseline in forced expiratory volume in one second (FEV1), area under curve from 0 to 3 hours post drug administration		baseline, day 29
Secondary	Change from baseline in forced vital capacity (FVC), area under curve from 0 to 3 hours post drug administration		baseline, day 29
Secondary	Change from baseline in total score of patient evaluation questionnaire		baseline, day 29
Secondary	Number of rescue medications		Up to day 29
Secondary	Trough forced vital capacity (FVC) response		baseline, day 29
Secondary	Number of patients with adverse events		up to day 29
Secondary	Changes in vital signs (blood pressure, pulse rate)		up to day 29
Secondary	Changes in electrocardiogram		up to day 29
Secondary	Changes in safety laboratory tests		up to day 29